Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered
Main Authors: | Joel Hanhart, Sohee Jeon, Raimo Tuuminen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-10-01
|
Series: | Journal of Diabetes |
Online Access: | https://doi.org/10.1111/1753-0407.13468 |
Similar Items
-
Should ACOG reconsider their criteria for the early diagnosis of hypertension in pregnancy?
by: Farrah Naz Hussain, et al.
Published: (2019-08-01) -
Should Multifocal Intraocular Lenses Become a Standard in Phacoemulsification Cataract Surgery?
by: Achia Nemet, et al.
Published: (2023-03-01) -
Should we reconsider platelet content criteria for single donor platelets in West Bengal, India?
by: Rizwan Javed, et al.
Published: (2017-01-01) -
Why Europe Should Reconsider its Anti-Arbitration Policy in Investment Disputes
by: Alan Uzelac
Published: (2019-03-01) -
Predicting enrollment performance of investigational centers in phase III multi-center clinical trials
by: Rutger M. van den Bor, et al.
Published: (2017-09-01)